ClinicalTrials.gg
RecruitingNCT07530640Updated Jun 16, 2026

Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities

A Phase 3 interventional study of atorvastatin of dose level 1 and atorvastatin of dose level 2 in Kawasaki Disease and Coronary Artery Abnormalities, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Children's Hospital of Fudan University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University — 5 open to participants now, 5 under way, 2 of them phase 3. Mucocutaneous Lymph Node Syndrome · Children's Hospital of Fudan University.

Started
2026
with 1 other
Phase 3
4 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University, this one is one of 2 that started in 2026, is one of 4 in phase 3, and was the 10th registered.

Mucocutaneous Lymph Node Syndrome

62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.

Browse Mucocutaneous Lymph Node Syndrome studies →

Open to participants now

5 of the 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 12 Mucocutaneous Lymph Node Syndrome studies recruiting now, 1 (8%) sets no upper age limit and 11 (92%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the safety and effects of atorvastatin in treatment of Chinese Kawasaki disease (KD) children complicated with coronary artery abnormalities (CAA) in acute phase. The main questions it aims to answer are: Is atorvastatin safe in Chinese children of acute KD? Does atorvastatin contribute to control the acute inflammation in KD and improve the CAA?

Read the detailed description

Kawasaki disease (KD) is acute self-limited vasculitis and occurs almost exclusively in childhood. It predominantly affects medium-sized arteries, most commonly coronary arteries. Although the use of intravenous immunoglobulin (IVIG) has obviously decreased the incidence of coronary arteries abnormalities (CAA), still a part of KD children occurs CAA, even medium, large or giant CA aneurysms. Coronary aneurysms can develop thrombus and arterial stenosis, which may cause severe cardiac events. Now KD has been the main cause of acquired heart disease in children in most areas of China mainland.

Studies have found that during the acute phase of KD, necrotizing arteritis occurs in coronary arteries. Oxidative stress, immune activation, and cellular infiltration of the vessel wall associated with secretion of proinflammatory cytokines, elastases, and matrix metalloproteinases (MMPs) are related to formation of coronary aneurysms. In addition, long-term KD vasculopathy appears ongoing vascular chronic inflammation and oxidative stress. Endothelial dysfunction, increased stiffness, and intima-media thickening have been noted in affected coronary arteries.

Statins, a hydroxymethylglutaryl coenzyme-A reductase inhibitors, has been widely used in adults for years not only for its reducing plasma cholesterol but also for its beneficial pleiotropic effects, including inflammation modulation, oxidative stress, endothelial function and angiogenesis, antithrombotic and antiplatelet effects. In recent years, statins have been considered to be used in KD children with coronary aneurysms. Several studies have shown reductions in high-sensitivity CRP, improved endothelial function and safety in such KD children treated with statins. The 2017 American Heart Association (AHA) scientific statement on KD has suggested that empirical treatment with low-dose statin may be considered for KD patients with past or current aneurysms, regardless of age or sex. The investigators have also conducted a follow-up study of atorvastatin used in long-term treatment of KD children with severe CAA. The results showed that long-term atorvastatin treatment was safe in Chinese KD children with CAA, but its dose was significantly lower than those been reported by previous studies abroad.

Based on the effects of statins on inhibition of MMP secretion and myofibroblast transformation which may anticipate the formation of CAA in acute KD, statins have been tried to be used in acute KD children with CAA. However, the relevant clinical data is very rare.Is atorvastatin safe in Chinese children of acute KD? Can atorvastatin actually contribute to control the acute inflammation of KD and improve CAA? The goal of this study is to learn about the safety and effects of atorvastatin in treatment of Chinese KD children complicated with CAA in acute phase.

03

Conditions studied

  • Kawasaki Disease
  • Coronary Artery Abnormalities

Keywords

  • Kawasaki Disease
  • Coronary artery abnormalities
  • Atorvastatin
  • Acute
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • KD complicated with CAA, less than 20 days after the onset of KD, or more than 20 days after onset but the KD inflammation has not been controled.
  • IVIG and/or other anti-inflammatory treatments have been used/are being used.
  • The guardians agree to atorvastatin treatment and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Patients with history of family hypercholesterolemia/taking statins/severe chronic diseases.
  • Patients with abnormal laboratory data including CK≥500U/L, total cholesterol\<3.1mmol/L, or AST≥ 2 times the .
  • The guardians do not agree to atorvastatin treatment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    statin group-level 1

    Participants will receive atorvastatin of dose level 1 (0.15 mg/kg/day) for 6 weeks on the basis of conventional therapy.

    Drug: atorvastatin of dose level 1

  • Experimental
    statin group-level 2

    Participants will receive atorvastatin of dose level 2 (0.25 mg/kg/day) for 6 weeks on the basis of conventional therapy.

    Drug: atorvastatin of dose level 2

  • Experimental
    statin group-level 3

    Participants will receive atorvastatin of dose level 3 (0.4 mg/kg/day) for 6 weeks on the basis of conventional therapy.

    Drug: atorvastatin of dose level 3

  • No intervention
    Control group

    Participants will only receive conventional therapy.

Interventions

  • Drugatorvastatin of dose level 1

    The study is to be designed as dose-escalation protocol and enroll a minimum of 3 subjects per dose level (level 1, 0.15 mg/kg/day; level 2, 0.25 mg/kg/day; level 3, 0.4 mg/kg/day). Participants will take atorvastatin for 6 weeks. The dose-limiting toxicities (DLTs) are used to determine the maximum tolerated dose (MTD).

  • Drugatorvastatin of dose level 2

    The study is to be designed as dose-escalation protocol and enroll a minimum of 3 subjects per dose level (level 1, 0.15 mg/kg/day; level 2, 0.25 mg/kg/day; level 3, 0.4 mg/kg/day). Participants will take atorvastatin for 6 weeks. The dose-limiting toxicities (DLTs) are used to determine the maximum tolerated dose (MTD).

  • Drugatorvastatin of dose level 3

    The study is to be designed as dose-escalation protocol and enroll a minimum of 3 subjects per dose level (level 1, 0.15 mg/kg/day; level 2, 0.25 mg/kg/day; level 3, 0.4 mg/kg/day). Participants will take atorvastatin for 6 weeks. The dose-limiting toxicities (DLTs) are used to determine the maximum tolerated dose (MTD).

06

What researchers measure

Primary outcomes

  1. Incidence of statin-associated side effects in Chinese acute KD children with CAA

    Safety evaluation of atorvastatin in acute KD children, referring to the incidence of statin-associated side effects (SASE). SASE include statin-associated clinical adverse events, elevated transaminase, creatine kinase, blood glucose and hypocholesterolemia.

    Time frame: Before, 2 weeks and 6 weeks after taking atorvastatin

Secondary outcomes

  1. Change of levels of high-sensitivity C reactive protein (sCRP)

    Changes of levels of high-sensitivity C reactive protein (sCRP) which reflex the acute KD inflammation

    Time frame: Before, 1 week, 2 weeks and 6 weeks after taking atorvastatin

  2. Change of levels of serum amyloid A(SAA)

    Change of levels of serum amyloid A(SAA) which reflex the acute KD inflammation

    Time frame: Before, 1 week, 2 weeks and 6 weeks after taking atorvastatin

  3. Change of levels of interleukin-6 (IL-6)

    Change of levels of interleukin-6 (IL-6) which reflex the acute KD inflammation

    Time frame: Before, 1 week, 2 weeks and 6 weeks after taking atorvastatin

  4. Change of levels of NT-proBNP

    Change of levels of NT-proBNP which reflex the acute KD inflammation

    Time frame: Before, 2 weeks and 6 weeks after taking atorvastatin

  5. Change of levels of albumin

    Change of levels of albumin which reflex the acute KD inflammation

    Time frame: Before, 1 week, 2 weeks and 6 weeks after taking atorvastatin

  6. Changes of sizes of involved coronary arteries measured by echocardiography

    Changes of diameters of involved coronary artery aneurysms

    Time frame: Before, 2 weeks and 6 weeks after taking atorvastatin

  7. Changes of diameter-Z score of involved coronary arteries measured by echocardiography

    Changes of Z score of involved coronary artery aneurysms diameters

    Time frame: Before, 2 weeks and 6 weeks after taking atorvastatin

  8. Changes of degrees of other echocardiographic findings

    Changes of degrees of other echocardiographic findings which reflex the acute KD inflammation, including mitral regurgitation and pericardial effusion

    Time frame: Before, 2 weeks and 6 weeks after taking atorvastatin

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 15, 2026
StartActual
Jun 8, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Sep 30, 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07530640
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Jun 8, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Chen Chu, MD
Contact
chickenchu@163.com
+86 21 64932026
Fang Liu, MD
Contact
liufang@fudan.edu.cn
+86 21 64932800
Chen Chu, MD
study director · Children's Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion